Bio-Thera Solutions Past Earnings Performance
Past criteria checks 0/6
Bio-Thera Solutions has been growing earnings at an average annual rate of 16.9%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 34.9% per year.
Key information
16.9%
Earnings growth rate
21.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 34.9% |
| Return on equity | -44.6% |
| Net Margin | -45.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bio-Thera Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 825 | -378 | 255 | 758 |
| 30 Jun 24 | 792 | -378 | 228 | 751 |
| 31 Mar 24 | 711 | -371 | 211 | 709 |
| 31 Dec 23 | 705 | -395 | 201 | 769 |
| 30 Sep 23 | 534 | -607 | 187 | 804 |
| 30 Jun 23 | 541 | -565 | 189 | 770 |
| 31 Mar 23 | 536 | -513 | 184 | 705 |
| 31 Dec 22 | 455 | -480 | 174 | 616 |
| 30 Sep 22 | 803 | -62 | 191 | 593 |
| 30 Jun 22 | 737 | -90 | 201 | 582 |
| 31 Mar 22 | 850 | 81 | 210 | 549 |
| 31 Dec 21 | 837 | 82 | 216 | 543 |
| 30 Sep 21 | 492 | -263 | 221 | 539 |
| 30 Jun 21 | 463 | -267 | 209 | 546 |
| 31 Mar 21 | 223 | -513 | 181 | 594 |
| 31 Dec 20 | 183 | -513 | 164 | 563 |
| 30 Sep 20 | 106 | -501 | 115 | 522 |
| 30 Jun 20 | 49 | -551 | 86 | 529 |
| 31 Mar 20 | 20 | -600 | 71 | 567 |
| 31 Dec 19 | 1 | -1,023 | 401 | 637 |
| 30 Sep 19 | 1 | -1,075 | 408 | 1,053 |
| 31 Dec 18 | 0 | -553 | 26 | 542 |
| 31 Dec 17 | 2 | -236 | 12 | 237 |
| 31 Dec 16 | 3 | -137 | 11 | 132 |
Quality Earnings: 688177 is currently unprofitable.
Growing Profit Margin: 688177 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688177 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare 688177's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688177 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688177 has a negative Return on Equity (-44.57%), as it is currently unprofitable.